Hence, although CXCR2 antagonism alone delivered modest model-dependant antitumour benefit, similar to observations made in models of non-hepatic cancers,26–31 we show that CXCR2 inhibition sensitises to anti-PD1 immunotherapy in models of NASH-HCC that are otherwise resistant to anti-PD1 monotherapy. The gene discussed is CXCR2; the disease is liver cancer.